Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.91
CYTR's Cash to Debt is ranked lower than
68% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. CYTR: 2.91 )
Ranked among companies with meaningful Cash to Debt only.
CYTR' s Cash to Debt Range Over the Past 10 Years
Min: 2.91  Med: 10000.00 Max: No Debt
Current: 2.91
Equity to Asset 0.66
CYTR's Equity to Asset is ranked lower than
52% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CYTR: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
CYTR' s Equity to Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.80 Max: 0.97
Current: 0.66
0.16
0.97
F-Score: 3
Z-Score: -6.22
M-Score: -4.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -59693.00
CYTR's Operating margin (%) is ranked lower than
98% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. CYTR: -59693.00 )
Ranked among companies with meaningful Operating margin (%) only.
CYTR' s Operating margin (%) Range Over the Past 10 Years
Min: -63278  Med: -9129.80 Max: -80.47
Current: -59693
-63278
-80.47
Net-margin (%) -53705.00
CYTR's Net-margin (%) is ranked lower than
97% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. CYTR: -53705.00 )
Ranked among companies with meaningful Net-margin (%) only.
CYTR' s Net-margin (%) Range Over the Past 10 Years
Min: -58587  Med: -3290.42 Max: 408
Current: -53705
-58587
408
ROE (%) -114.12
CYTR's ROE (%) is ranked lower than
85% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. CYTR: -114.12 )
Ranked among companies with meaningful ROE (%) only.
CYTR' s ROE (%) Range Over the Past 10 Years
Min: -271.11  Med: -86.58 Max: 1.39
Current: -114.12
-271.11
1.39
ROA (%) -75.53
CYTR's ROA (%) is ranked lower than
81% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. CYTR: -75.53 )
Ranked among companies with meaningful ROA (%) only.
CYTR' s ROA (%) Range Over the Past 10 Years
Min: -116.2  Med: -46.69 Max: 1.13
Current: -75.53
-116.2
1.13
ROC (Joel Greenblatt) (%) -4959.29
CYTR's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CYTR: -4959.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12894.39  Med: -3246.77 Max: -723.27
Current: -4959.29
-12894.39
-723.27
Revenue Growth (3Y)(%) -20.60
CYTR's Revenue Growth (3Y)(%) is ranked lower than
73% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CYTR: -20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.8  Med: -34.00 Max: 175.3
Current: -20.6
-81.8
175.3
EBITDA Growth (3Y)(%) 4.50
CYTR's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CYTR: 4.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.6  Med: -10.30 Max: 143.5
Current: 4.5
-68.6
143.5
EPS Growth (3Y)(%) 7.40
CYTR's EPS Growth (3Y)(%) is ranked higher than
66% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. CYTR: 7.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55  Med: -12.00 Max: 75.1
Current: 7.4
-55
75.1
» CYTR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

CYTR Guru Trades in

CYTR Guru Trades in

CYTR Guru Trades in

Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:RNUGF, NAS:AKTX, NYSE:EVGN, NAS:ZFGN, AMEX:PIP, OTCPK:VRACY, NAS:DMTX, AMEX:SYN, NAS:AVXL, OTCPK:RCAR, NAS:ATHX, OTCPK:MDGEF, OTCPK:MXDHF, NAS:IMDZ, NAS:CDXS, OTCPK:CTIX, AMEX:AMPE, NAS:CMRX, OTCPK:SPHRY, NAS:MDWD » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.

CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
P/B 4.69
CYTR's P/B is ranked lower than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CYTR: 4.69 )
Ranked among companies with meaningful P/B only.
CYTR' s P/B Range Over the Past 10 Years
Min: 1.43  Med: 3.86 Max: 67.04
Current: 4.69
1.43
67.04
P/S 1185.00
CYTR's P/S is ranked lower than
97% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. CYTR: 1185.00 )
Ranked among companies with meaningful P/S only.
CYTR' s P/S Range Over the Past 10 Years
Min: 3.49  Med: 280.00 Max: 2565
Current: 1185
3.49
2565
Current Ratio 3.86
CYTR's Current Ratio is ranked lower than
55% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYTR: 3.86 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.37 Max: 27.1
Current: 3.86
1.04
27.1
Quick Ratio 3.86
CYTR's Quick Ratio is ranked lower than
53% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CYTR: 3.86 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.30 Max: 27.1
Current: 3.86
1.04
27.1
Days Sales Outstanding 3.00
CYTR's Days Sales Outstanding is ranked higher than
95% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. CYTR: 3.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.94  Med: 235.06 Max: 16870.3
Current: 3
4.94
16870.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.93
CYTR's Price/Net Cash is ranked lower than
52% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. CYTR: 5.93 )
Ranked among companies with meaningful Price/Net Cash only.
CYTR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.55  Med: 5.36 Max: 458
Current: 5.93
0.55
458
Price/Net Current Asset Value 5.04
CYTR's Price/Net Current Asset Value is ranked higher than
50% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. CYTR: 5.04 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.43  Med: 4.27 Max: 108.89
Current: 5.04
0.43
108.89
Price/Tangible Book 4.72
CYTR's Price/Tangible Book is ranked lower than
56% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. CYTR: 4.72 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.34  Med: 3.55 Max: 63.61
Current: 4.72
0.34
63.61
Price/Median PS Value 4.24
CYTR's Price/Median PS Value is ranked lower than
92% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. CYTR: 4.24 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.22 Max: 6.64
Current: 4.24
0.01
6.64
Earnings Yield (Greenblatt) (%) -52.60
CYTR's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. CYTR: -52.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 572.4  Med: 1854.10 Max: 12962.6
Current: -52.6
572.4
12962.6

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -0.85
Beta2.41
Short Percentage of Float21.39%
52-Week Range $1.55 - 4.20
Shares Outstanding (Mil)66.76

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 17 41
EPS ($) -0.92 -0.46 -0.05
EPS w/o NRI ($) -0.92 -0.46 -0.05
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CYTRX CORP Files SEC form 8-K, Other Events Jun 07 2016
CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical... Jun 06 2016
CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical... Jun 06 2016
CytRx to Present at Jefferies 2016 Global Healthcare Conference May 31 2016
CytRx to Present at Jefferies 2016 Global Healthcare Conference May 31 2016
CYTRX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities May 27 2016
CYTRX CORP Financials May 19 2016
Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City May 12 2016
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition May 11 2016
CytRx reports 1Q loss May 11 2016
CytRx reports 1Q loss May 11 2016
CytRx Reports First Quarter 2016 Financial Results May 11 2016
CYTRX CORP Files SEC form 10-Q, Quarterly Report May 10 2016
CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail May 10 2016
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference Apr 28 2016
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference Apr 28 2016
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the... Apr 25 2016
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the... Apr 25 2016
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical... Apr 20 2016
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical... Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)